We, therefore, conducted a systematic clinical and molecular study of adult patients with RRM2B mutation(s) to define the phenotypic spectrum of adult RRM2B-related mitochondrial disease and establish any genotype phenotype correlations.
COSMIC database contains sequencing data for 8 out of 10 cell lines with TP53 mutations listed in Table 1 of my manuscript containing cell lines with inactivated TP53 in the validation set of cell lines considered to be TP53 wild type by Jeay et al. COSMIC database contains identical TP53 mutation(s) to the ones listed in Table 1 for each of these 8 cell lines.
These results suggested that progeny viruses from the MAMM mutant might contain adaptive mutation(s) to counteract the inhibitory effect of the NA inhibitor.
While FemX was shown to be essential [ 7], femAB null mutants were postulated to require a secondary, yet uncharacterized compensatory or suppressor mutation(s) chr* to stabilize the cell [ 6].
However, mutations in the Ime2 consensus site in VIB-1 that are predicted to result in phospho-null mutations (S to A) or activating mutations (S to D) resulted in no to only subtle phenotypic differences from WT.
To visualize the results, we use the U-shaped plot of extinction time as a function of the selection coefficient against deleterious mutations (s), to characterize the range of critical selection coefficients s c between which extinction is expected to occur in a given interval of time [ 6, 9].
Therefore, we retrospectively analyzed repeated sweat chloride values obtained in patients with G551D mutation(s) assigned to placebo in an ivacaftor interventional trial.
Recently, a C. glutamicum strain has been optimized for growth on defined medium containing d-xylose by laboratory evolution, but the mutation(s) attributing to the improved-growth phenotype could not be reliably identified.
There is also an increased sensitivity or likelihood of detecting an affected individual's disease-causing mutation(s) due to the analysis of multiple genes simultaneously.
Other causes of misfolding and misfunction include point mutation(s), exposure to internal or external toxins, impaired posttranslational modifications (phosphorylation, advanced glycation, deamidation, racemization, acetylation, etc)., an increased probability of degradation, impaired trafficking, loss of binding partners or oxidative damage.
It has then become important to evaluate the potential surrogate markers of these EGFR-TKI agents in addition to the presence or absence of EGFR mutation(s) in order to increase the response rate to these agents.
